(May 14, 2009) — A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Un tremblement de terre dans le domaine des essais clinique a démontré qu'un médicament anti-viral commun, le ribavirin peut être bénifique dansle traitement du cancer.
The study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.L'étude démontre que le ribavirin supprime l'activité du gène eIF4E. Ce gène est dérégulé dans 30% des patients du cancers incluants les cancers du de la du du et de l'estomac.
The study, inspired by the exciting discoveries made by Dr. Borden at IRIC, was a joint project between her research group, who monitored molecular events in trial patients, and Dr. Sarit Assouline of the Segal Cancer Centre, Jewish General Hospital, who led the clinical part of the trial.
The integration of these two teams made it possible to rapidly move from a research lab to patient tests. The study team targeted the gene by giving trial participants a mimic of its natural target, ribavirin. "Our results are the first to show that targeting eIF4E in humans is clinically beneficial," explains Dr. Borden. "We also found that ribavirin not only blocks eIF4E, it has no side effect on patients."Le médicament n'a pas d'effets secondaires.
The trial studied patients with M4/M5 acute myeloid leukemia who had undergone several other treatments that had previously failed. "We had striking clinical improvements with even partial and complete remissions," indicated Assouline.
Dr. Wilson Miller, director of the Clinical Research Unit, Jewish General Hospital, and co-investigator in the trial added: "It's rare that discoveries in basic research move to clinical so quickly and successfully."C'est rare qu'une découverte en recherche fondamentale aille si rapidement en essais clinique et avec tant de succès.
The next challenge for this team is to overcome the resistance that develops over time to ribavirin. "Combination therapy with chemotherapeutic agents may enhance the efficacy of this treatment," explains Borden, "Trials in the near future are planned to overcome this and we are looking forward to more complete remissions. We also hope to test whether ribavirin is as effective in the treatment of other cancers with dysregulated eIF4E. Our laboratory studies suggest this is likely."La prochaine étape consistera à vaincre la résistance que les patients développent avec le temps au ribavirin. "Les essais cliniques vont être planifiés pour essayer de vaincre cette résistance et nous recherchons plus de rémissions complètes. nous voulons savoir aussi si le ribavirin sera aussi eficace dans le traitement de dA'utres cancers avec le gène EeIF4E dérégulé.
The study team also included Drs. Brian Leber from McMaster University/Hamilton Health Sciences (Ontario) and Denis-Claude Roy from Hôpital Maisonneuve-Rosemont in Montreal. The study was made possible thanks to a $600,000 grant awarded to Dr. Borden by The Leukemia and Lymphoma Society (USA).
Dr. Sarit Assouline of the Segal Cancer Centre, Jewish General Hospital, who led the clinical part of the trial.